EGFR and lymphangioma: After the onset of LM, 23 patients (74.19%) were treated with third-generation EGFR-TKIs (osimertinib, furmonertinib, or aumolertinib), of whom 18 (58.06%) were treated with high-dose third-generation EGFR-TKIs.